|
|
||||||||
1 Department of Cardiology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; 2 Research Group for Experimental and Clinical Arteriogenesis at the Department for Cardiology and Angiology, Albert-Ludwigs University Freiburg, D-79106 Freiburg; 3 Boehringer Ingelheim Pharma KG, D88397 Biberach; and 4 Max-Planck-Institute for Experimental Cardiology, D-61231 Bad Nauheim, Germany
| |
ABSTRACT |
|---|
|
|
|---|
For an appropriate extrapolation to
patients with peripheral arterial obstructive disease, we tested the
efficacy of monocyte chemoattractant protein 1 (MCP-1) treatment in a
porcine hindlimb ligation model. In 40 minipigs, a femoral artery
ligation was performed. Control animals were examined immediately after
ligation (n = 4) or after 2 wk of intra-arterial
infusion of PBS (n = 11). A second group of animals was
evaluated after intra-arterial infusion of 2.0 µg/h of MCP-1 for
48 h (followed by 12 days of PBS; n = 13) or 2 wk
continuously (n = 12). In the terminal experiment after
2 wk, resting flow to the leg and peripheral arterial pressures were
assessed without vasodilatation. Subsequently, vascular conductance was
determined by using a pump-driven extracorporal circulation during
maximal vasodilatation. The results showed that resting blood flow to
the hindlimb was 53% of the normal after 2 wk of infusion of PBS,
compared with 81% in both MCP-1 treatment groups (P < 0.05). Collateral conductance was 645 ± 346 ml · min
1 · mmHg
1
after 2 wk of infusion with PBS, compared with 1,070 ± 530 and 1,158 ± 535 ml · min
1 · mmHg
1
after 48 h and 2 wk treatment with MCP-1, respectively
(P < 0.05). Modulation of the process of
arteriogenesis is feasible in this large animal model via
intra-arterial infusion of the Cys-Cys-chemokine MCP-1.
peripheral arterial obstructive disease; intervention; growth factor
| |
INTRODUCTION |
|---|
|
|
|---|
PATIENTS with obstructive peripheral or coronary disease may benefit from the progress made during the last decades in both medical and invasive treatment modalities focusing on the restoration of blood flow. Nevertheless, the group of patients that remains symptomatic, despite these currently available treatment options, is still growing and therefore constitutes a major clinical problem in the Western world (12, 28). The potential stimulatory effect of growth factor administration on vessel formation has created a possible new treatment option for this patient group (7, 17). It is important to distinguish two different forms of compensatory vessel growth, angiogenesis and arteriogenesis, as has recently been recognized by several other groups (4, 10, 11, 19, 33). Angiogenesis refers to the formation of new small capillaries in response to ischemia. Arteriogenesis refers to the remodeling of preexisting arterioles to mature collateral arteries. In this process, not ischemia, but increased shear stress due to redistribution of blood over these arterioles, is the driving force for the remodeling of these vessels into true collateral arteries (24, 32). Most likely, the therapeutic stimulation of arteriogenesis is to be preferred over angiogenesis, because arteriogenesis is more efficient to compensate flow reduction due to the larger diameter and better functionality of the formed vessels compared with capillary networks in angiogenesis (28). A number of experimental peripheral ligation models in mainly small animals have been used to study the stimulation of these processes with growth factors (13, 15). In these studies, monocyte chemoattractant protein 1 (MCP-1) has been shown to be one of the strongest stimulators of the arteriogenesis process. The purpose of the present study was to evaluate the potency of MCP-1 for the stimulation of collateral artery growth in a porcine hindlimb ligation model that may be more suitable for the extrapolation of the observed effects to patients with peripheral arterial obstructive disease.
| |
METHODS |
|---|
|
|
|---|
Surgical preparation. For this study 40 Göttinger minipigs of either sex and weighing 28 ± 6 kg (Ellegaard; Dalmose, Denmark) were used. The animals were handled in accordance with the American Physiological Society guidelines for animal welfare. Animals were housed in standard cages and fed water and chow ad libitum. The pigs were sedated with a combination of azaperone (5 ml, 40 mg/ml), midazolam (3 ml, 5 mg/ml), and ketamine hydrochloride (2 ml, 100 mg/ml) and were subsequently intubated and ventilated with a respirator (Engström 300, Engström Medical; Solna, Sweden) with N2O-O2 in a ratio of 2:1. General anesthesia was maintained with isoflurane (0.8 to 2.0 vol% in O2). The left arteria femoralis was exposed using a sterile surgical technique and ligated immediately distal from the bifurcation with the arteria profunda femoris. A double ligation was performed with a 4-cm distance in between the two ligation sites. Also, the arteria circumflexa femoris lateralis was ligated to prevent "bridging" collateral artery formation.
Intra-arterial infusion. A 1.6-mm silicon infusion catheter was retrogradely inserted with the tip placed just distal to the bifurcation to ensure a first-pass effect of the compound over the collateral vascular bed. The catheter was subcutaneously tunneled to the animal's back and externalized and connected to a portable elastomeric infusion system (2.0 ml/h, Multiday Infusor; Baxter Healthcare). The animals were examined acutely after ligation (n = 4), after 2 wk infusion with vehicle (PBS; n = 11), or after treatment with 2.0 µg/h monocyte chemoattractant protein 1 (recombinant MCP-1, Boehringer Ingelheim) for 48 h, followed by 12 days of vehicle (n = 13) or 2 wk continuous infusion of MCP-1 (n = 12).
Experimental design.
For the terminal study after 2 wk of ligation, the animals were
anesthetized again with the previously described doses of azaperone,
ketamine, and midazolam. Anesthesia was subsequently maintained by the
administration of pentobarbital sodium (60 mg/animal bolus, followed by
a continuous intravenous infusion in a dose of 10 mg · kg
1 · h
1).
The jugular vein was cannulated for the maintenance of the anesthesia.
Heparin was injected in a dose of 20,000 IU/animal. The animals were
monitored during the experiment by using ECG, and heart rate and
arterial oxygenation were measured by using a pulse oximetry. A
solid-state pressure gauge manometer was placed in the left carotid
artery for the continuous measurement of systemic arterial pressure.
The saphenous arteries were exposed at the level of the metatarsus and
cannulated with fluid-filled polyethylene catheters. These tubings were
connected to pressure transducers for the measurement of distal
arterial pressure. With the use of a laparotomy, the abdominal aorta
and both arteria iliacae externae were isolated. For the measurement of
volume flow to the region of interest, flow probes (Transonic Systems;
Ithaca, NY) were placed around each of the arteria iliacae externae
just proximal of the bifurcation of the arteria femoralis and the
arteria profunda femoris. The mesenteric artery was cannulated with a polyethylene-heparinized catheter for the measurement of the perfusion pressure after installation of an extracorporal circulatory system. For
this extracoporal system, the aorta was dissected, and specially designed glass cannulas were inserted proximally and distally into the
aorta immediately before the aortic bifurcation. The glass cannulas
were connected at both ends to a silicone tube (aortic bypass). The
silicone tube was inserted into an electronic roller pump (ISM 726, Ismatec; Wertheim, Germany) for controlled perfusion of the hindlimbs.
After a steady state was reached, papaverine-HCl (Sigma Chemicals; St.
Louis, MO) was continuously infused in a dose of 20 mg/min into the
perfusion line to achieve a stable maximal local vasodilatation. The
pump speed was then stepwise increased until the systemic blood supply
was exhausted. Each step was maintained until a stable flow was
achieved. Continuous hemodynamic recordings were made using the data
acquirement software Notocord-Hem 3.3 (Notocord systems; Croissy, France).
In vivo angiography. In four minipigs (2 PBS-treated and 2 2-wk MCP-1-treated animals), a sheath was inserted directly into the right carotid artery, and a 7-F diagnostic catheter was positioned in either the distal iliac artery or the arteria profunda femoris for the selective injection of a single 20- to 50-ml bolus of nonionic contrast agent (Solutrast 300, Byk Gulden; Konstanz, Germany). Images were digitally recorded on a desktop personal computer.
Hemodynamic measurements. Before the insertion of the extracorporal circulatory system, values of the mean left and right resting blood flow through the arteria iliaca externa and the mean left and right peripheral and central blood pressures were assessed without the use of vasodilatation. Subsequently, the pump-driven extracorporal circulatory system was applied to control perfusion pressures to the legs. With the use of this technique, perfusion pressure was enhanced in several steps under continuous maximal vasodilatation using papaverine. Both femoral artery volume flow and pressure gradient over the ligated and unligated arteria femoralis were assessed for the calculation of arterial conductance.
Histology. A contrast medium, based on barium sulfate, was infused into the donor artery (arteria profunda femoris) for macroscopical detection of the collateral arteries (n = 4; 2 PBS-treated and 2 2-wk MCP-1-treated animals). Tissue samples were taken after identification of the formed collateral arteries based on recognition of the typical stem, midzone and reentry region, and corkscrew appearance. Histological sections (5 µm) were prepared from paraffin-embedded tissue samples and were evaluated for morphological appearance with hematoxylin-eosin staining. For detection of proliferating vascular wall cells, frozen sections (5 mm thick) were placed on gelatin-coated slides and fixed for 10 min in acetone. Tissue sections were then exposed for 10 min in 0.1% carboxylated bovine serum albumin in PBS, followed by incubation overnight at 4°C with a primary monoclonal antibody against Ki-67 (clone MIB-1). After repeated washes in PBS, the sections were then incubated for 1 h in RT with goat anti-mouse IgG conjugated with FITC. Specificity of the labeling was confirmed by omission of the primary antibody. Nuclei were stained with Hoechst 33342.
Data analysis.
Values of volume flow and pressure were obtained during the
plateau of each perfusion level and were averaged. The assessed flows
and pressure gradients were subsequently fitted in a linear regression.
All conductance indexes were calculated from the equation of the
pressure-flow relation as the flow level of the distal vascular bed at
a pressure (P) gradient (Pperfusion
Pdistal) of 100 mmHg. Animals were excluded if the
linear fit of the conductance calculation did not result in a
regression coefficient (r2) > 0.94 in one of the legs. Results are expressed as means ± SD.
Differences between sample means were determined with an ANOVA with a
Dunnett's (post) test and were considered statistically significant
when the P value was < 0.05.
| |
RESULTS |
|---|
|
|
|---|
No differences were present regarding age and body weight
between the different treatment groups (Table
1).
|
Angiography.
Examples of in vivo angiographies of animals that received PBS for 2 wk
or that were treated for 2 wk with MCP-1 are shown in Fig.
1. Collateral arteries, connecting the
arteria profunda femoris (stem zone) and the distal zone of the femoral
artery (reentry zone), could be observed.
|
Resting blood flow and pressures.
The resting blood flow and peripheral pressures of all treatment
groups are depicted in Table 2. Heart
rate, systemic pressure, and distal pressure and blood flow in the
unligated leg remained similar in all animal groups. Blood flow and
distal pressure in the ligated leg increased after 2 wk of vehicle
infusion. Whereas distal pressure did not show a significant increase
(55 ± 12, 57 ± 11, and 57 ± 11 mmHg after 2 wk of PBS
and 2 days and 2 wk of MCP-1, respectively; P = not
significant), blood flow increased after treatment with MCP-1 (from
54 ± 30 to 105 ± 60 ml/min and 88 ± 38 ml/min after 2 wk of PBS and 2 days and 2 wk of MCP-1, respectively; P < 0.05). Figure 2 shows that resting
blood flow to the leg increased from 27% of the contralateral leg
after acute ligation to 53% after 2 wk of treatment with vehicle
(P < 0.05). This is in contrast with a marked increase
of flow after 2 days of treatment with MCP-1 (81%; P < 0.05), although this flow did not further increase if MCP-1
administration was extended to 2 wk (81%). Distal pressures increased
from 45% of the normal directly after ligation to 73%, 75%, and 76%
after 2 wk of the vehicle infusion and 2 days and 2 wk of treatment
with MCP-1, respectively (P = not significant).
Likewise, no statistically significant differences were present
regarding the calculated ratio of the systemic and peripheral pressure
("ankle-brachial index") between the groups of animals that were
treated with either vehicle or MCP-1.
|
|
Conductance measurements.
Figure 3A shows that
acutely after ligation, conductance over the distal vascular bed
decreased to a value of 158 ± 112 ml · min
1 · 100 mmHg
1. After 2 wk of infusion with PBS, conductance
increased to 645 ± 346 ml · min
1 · 100 mmHg
1 compared with 1,070 ± 530 and 1,158 ± 535 ml · min
1 · 100 mmHg
1 after 48 h and 2 wk treatment with MCP-1,
respectively (PBS compared with both MCP-1 groups; P < 0.05). Similar differences were observed when the conductance
was corrected for the conductance in the unligated leg (Fig.
3B).
|
Histology.
An increased number of inflammatory cells (monocytes/neutrophils)
were present in the perivascular space around developing collateral
arteries (Fig. 4). Furthermore, Ki67
staining for proliferating cells revealed dividing smooth muscle cells
in the tunica media of the developing collateral arteries (Fig.
5). Ki67 is a nuclear antigen expressed
by proliferating cells but downregulated in cells reentering the
G0 phase (26). However, no quantitative differences in the number of infiltrating cells or dividing smooth muscle cells could be observed between the MCP-1 treated and control animals.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
The present study demonstrates the efficacy of stimulation of collateral artery growth in a porcine hindlimb ligation model using exogenous administration of the C-C-chemokine MCP-1. Blood flow was increased twofold after 2 days of treatment, whereas extension of treatment to 2 wk did not further increase this positive effect on hindlimb perfusion.
Collateral artery growth in the peripheral circulation in pigs. It is has been shown previously that the pig has limited potential for the development of (endocardial) collateral arteries in the coronary circulation compared with the extensive (epicardial) coronary collateral vascular bed in the dog (8, 21, 30). For the hindlimb circulation, the development of collateral arteries in pigs has not been studied until now. The efficacy of different growth factors has been shown in the rabbit hindlimb model (2, 13, 15, 31). However, for the extrapolation of the effects of growth factors on arteriogenesis to the clinical situation of peripheral arterial obstructive disease, the present animal model is valuable because it enables the assessment of dose-effect relationships on arterial remodeling in a large animal. This effect may be markedly different in larger sized animals, considering the number of cell divisions required for maturation of the collateral vessels. As shown in the present study, no overt ischemic damage to the femoralis-perfused tissue was observed. Moreover, a spontaneous increase of blood flow after 2 wk ("natural course") was demonstrated. Angiography showed that the porcine hindlimb collateral circulation has a similar anatomy compared with the human situation according to Longland's classification (20). The pig hindlimb thus provides an excellent large animal model for the evaluation of collateral artery growth in the peripheral circulation, which provides a broad spectrum of functional hemodynamic parameters and allows the assessment of vascular conductance under conditions of maximal vasodilatation.
MCP-1 in arteriogenesis.
After obstruction of a main feeding artery, a redistribution of
blood flow occurs over the preexisting arterioles. The subsequent presence of increased intravascular shear stress due to the enhanced blood flow causes a local activation of the endothelium (14, 18,
23). This activated endothelium causes an upregulation of
monocyte adhesion receptors such as intercellular and vascular cell
adhesion molecule and endogenously produces factors such as
transforming growth factor-
and MCP-1 (6, 25, 27). MCP-1 is a potent agonist for the
-chemokine receptors CCR-2 and
CCR-4 that are expressed on monocytes (22). The presence of a gradient of MCP-1 induces chemotaxis of monocytes via this pathway. The attraction of monocytes, their diapedesis through the
vessel wall, transformation into macrophages, and finally, their local
production of a cocktail of factors is generally believed to be the
primary stimulatory mechanism for collateral vessel growth (1,
16). The cocktail of factors that is produced by the monocyte
[i.e., matrix metalloproteinases (MMPs), tumor necrosis factor-
(TNF-
), basic fibroblast growth factor (b-FGF), and platelet-derived
growth factor (PDGF)] facilitates a locally active process of mitosis
of endothelial and smooth muscle cells (5, 29). TNF-
and MMPs induce an inflammatory environment and the degradation of
existing structures, whereas b-FGF and PDGF stimulate mitogenesis of
endothelial and smooth muscle cells. This remodeling process leads to
the development of functional arteries with multiple smooth muscle
layers that are capable to carry substantial volumes of blood due to
their relatively low resistance and responsiveness to vasoactive
substances (i.e., during exercise). This is in contrast to the
development of small capillaries during angiogenesis, consisting
exclusively of endothelial cells (3). This is
important with respect to the functionality and capacity of these
vessels, because these vessels have to compensate for a substantial
amount of loss of blood flow after obstruction of a large feeding
artery, as also depicted in the current study (flow decrease of 75%).
In the present study, the accumulation of monocytes around the formed
collateral arteries was confirmed histologically, and it was shown that
the process of arteriogenesis in the porcine hindlimb could be
positively modulated using an intra-arterial administration of MCP-1.
This effect (leading to approximately a doubling of the spontaneous
increase of conductance) seems to be less pronounced compared with the
strong effects that were observed in the rabbit model (MCP-1-treated
three- to eightfold increase of conductance compared with PBS)
(13, 15). The total dose that was used in the 2 wk-treated
pigs is about five- to sixfold the dose (corrected for weight and
treatment period) as used in the rabbit studies. However, in the
animals that were treated for only 48 h, the total amount of MCP-1
per kilogram body weight that was administered was similar to the
amount used in the rabbit model. No further improvement of hindlimb
perfusion was observed after a prolonged duration (2 wk) of treatment
with MCP-1. This finding may be explained by the fact that local
attraction and extravasation of monocytes around a developing
collateral artery merely occur within the first days after acute
arterial occlusion (1, 16). Hence, a short duration of
MCP-1 infusion may be sufficient for the attraction and activation of
the monocytes, which are required for collateral artery growth.
End points. In the current study, assessment of hindlimb perfusion was performed after 2 wk of femoral artery ligation, irrespective of the treatment period. Although angiography and histology were performed, hemodynamic parameters were used as the primary end point to evaluate the effects of MCP-1 on hindlimb perfusion, because the correlation between the number of visible arteries and the grade of perfusion is generally believed to be doubtful (9). Relative small positive effects were observed on resting blood flow. However, no (statistical significant) effects were seen on resting peripheral pressures and on the calculated ankle-brachial index (which is an end point in many clinical studies), which may be due to the high level of "spontaneous" recovery of the resting distal pressure to ~75% of normal. This reduces the therapeutic window for growth factor therapy for these end points. After induction of increasing perfusion pressures using the pump-driven system under maximal vasodilatation, the positive effects of MCP-1 treatment were detected more clearly. This result reflects the importance of using vasodilators and the testing of the maximal capacity of the vascular system, rather than only measuring at resting conditions.
In summary, our results have shown that collateral arteries develop in the pig hindlimb and that an improvement of perfusion can be achieved using intra-arterial administration of MCP-1. Moreover, our data show that 2 days of infusion of MCP-1 is sufficient to induce a significant arteriogenic response, whereas a longer duration of therapy did not further increase this proarteriogenic effect.| |
ACKNOWLEDGEMENTS |
|---|
Boehringer Ingelheim Pharma is acknowledged for financial and technical assistance in this project. T. Dietze, A. Sterner, and S. Germeyer contributed to this project.
| |
FOOTNOTES |
|---|
This work was supported by the German Volkswagenfoundation.
Address for reprint requests and other correspondence: J. J. Piek, Dept. of Cardiology, B1-108, Academic Medical Center, Meibergdreef 9, 1105 AZ Amsterdam, PO Box 22700, 1100 DE Amsterdam, The Netherlands (E-mail: j.j.piek{at}amc.uva.nl).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
First published December 27, 2002;10.1152/ajpheart.00506.2002
Received 18 June 2002; accepted in final form 26 December 2002.
| |
REFERENCES |
|---|
|
|
|---|
1.
Arras, M,
Ito WD,
Scholz D,
Winkler B,
Schaper J,
and
Schaper W.
Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb.
J Clin Invest
101:
40-50,
1998[Web of Science][Medline].
2.
Asahara, T,
Bauters C,
Zheng LP,
Takeshita S,
Bunting S,
Ferrara N,
Symes JF,
and
Isner JM.
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo.
Circulation
92:
II365-II371,
1995.
3.
Carmeliet, P.
Basic concepts of (myocardial) angiogenesis: role of vascular endothelial growth factor and angiopoietin.
Curr Interv Cardiol Rep
1:
322-335,
1999[Medline].
4.
Carmeliet, P.
Mechanisms of angiogenesis and arteriogenesis.
Nat Med
6:
389-395,
2000[Web of Science][Medline].
5.
Cavaillon, JM.
Cytokines and macrophages.
Biomed Pharmacother
48:
445-453,
1994[Medline].
6.
Chappell, DC,
Varner SE,
Nerem RM,
Medford RM,
and
Alexander RW.
Oscillatory shear stress stimulates adhesion molecule expression in cultured human endothelium.
Circ Res
82:
532-539,
1998
7.
Folkman, J.
Therapeutic angiogenesis in ischemic limbs.
Circulation
97:
1108-1110,
1998
8.
Freedman, SB,
and
Isner JM.
Therapeutic angiogenesis for ischemic cardiovascular disease.
J Mol Cell Cardiol
33:
379-393,
2001[Web of Science][Medline].
9.
Fuchs, S,
Shou M,
Baffour R,
Epstein SE,
and
Kornowski R.
Lack of correlation between angiographic grading of collateral and myocardial perfusion and function: implications for the assessment of angiogenic response.
Coron Artery Dis
12:
173-178,
2001[Web of Science][Medline].
10.
Fujita, M.
Heparin and angiogenic therapy.
Eur Heart J
21:
270-274,
2000
11.
Hershey, JC,
Baskin EP,
Glass JD,
Hartman HA,
Gilberto DB,
Rogers IT,
and
Cook JJ.
Revascularization in the rabbit hindlimb: dissociation between capillary sprouting and arteriogenesis.
Cardiovasc Res
49:
618-625,
2001
12.
Hiatt, WR.
Medical treatment of peripheral arterial disease and claudication.
N Engl J Med
344:
1608-1621,
2001
13.
Hoefer, IE,
van Royen N,
Buschmann IR,
Piek JJ,
and
Schaper W.
Time course of arteriogenesis following femoral artery occlusion in the rabbit.
Cardiovasc Res
49:
609-617,
2001
14.
Houston, P,
Dickson MC,
Ludbrook V,
White B,
Schwachtgen JL,
McVey JH,
Mackman N,
Reese JM,
Gorman DG,
Campbell C,
and
Braddock M.
Fluid shear stress induction of the tissue factor promoter in vitro and in vivo is mediated by Egr-1.
Arterioscler Thromb Vasc Biol
19:
281-289,
1999
15.
Ito, WD,
Arras M,
Winkler B,
Scholz D,
Schaper J,
and
Schaper W.
Monocyte chemotactic protein-1 increases collateral and peripheral conductance after femoral artery occlusion.
Circ Res
80:
829-837,
1997
16.
Kern, M.
Angiogenesis, arteriogenesis, and physiological perfusion: Review of natural history and concepts.
J Interv Cardiol
12:
313-318,
1999[Web of Science].
17.
Kornowski, R,
Fuchs S,
Leon MB,
and
Epstein SE.
Delivery strategies to achieve therapeutic myocardial angiogenesis.
Circulation
101:
454-458,
2000
18.
Kosaki, K,
Ando J,
Korenaga R,
Kurokawa T,
and
Kamiya A.
Fluid shear stress increases the production of granulocyte-macrophage colony-stimulating factor by endothelial cells via mRNA stabilization.
Circ Res
82:
794-802,
1998
19.
Lloyd, PG,
Yang HT,
and
Terjung RL.
Arteriogenesis and angiogenesis in rat ischemic hindlimb: role of nitric oxide.
Am J Physiol Heart Circ Physiol
281:
H2528-H2538,
2001
20.
Longland, CJ.
The collateral circulation of the limb.
Ann R Coll Surg Engl
13:
161-176,
1953[Web of Science][Medline].
21.
Maxwell, MP,
Hearse DJ,
and
Yellon DM.
Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction.
Cardiovasc Res
21:
737-746,
1987[Web of Science][Medline].
22.
Olszak, IT,
Poznansky MC,
Evans RH,
Olson D,
Kos C,
Pollak MR,
Brown EM,
and
Scadden DT.
Extracellular calcium elicits a chemokinetic response from monocytes in vitro and in vivo.
J Clin Invest
105:
1299-1305,
2000[Web of Science][Medline].
23.
Schaper, J,
Konig R,
Franz D,
and
Schaper W.
The endothelial surface of growing coronary collateral arteries. Intimal margination and diapedesis of monocytes A combined SEM and TEM study.
Virchows Arch A Pathol Anat Histol
370:
193-205,
1976[Medline].
24.
Schaper, W,
and
Ito WD.
Molecular mechanisms of coronary collateral vessel growth.
Circ Res
79:
911-919,
1996
25.
Scholz, D,
Ito W,
Fleming I,
Deindl E,
Sauer A,
Wiesnet M,
Busse R,
Schaper J,
and
Schaper W.
Ultrastructure and molecular histology of rabbit hind-limb collateral artery growth (arteriogenesis).
Virchows Arch
436:
257-270,
2000[Web of Science][Medline].
26.
Scholzen, T,
and
Gerdes J.
The Ki-67 protein: from the known and the unknown.
J Cell Physiol
182:
311-322,
2000[Web of Science][Medline].
27.
Shyy, YJ,
Hsieh HJ,
Usami S,
and
Chien S.
Fluid shear stress induces a biphasic response of human monocyte chemotactic protein 1 gene expression in vascular endothelium.
Proc Natl Acad Sci USA
91:
4678-4682,
1994
28.
Simons, M,
Bonow RO,
Chronos NA,
Cohen DJ,
Giordano FJ,
Hammond HK,
Laham RJ,
Li W,
Pike M,
Sellke FW,
Stegmann TJ,
Udelson JE,
and
Rosengart TK.
Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary.
Circulation
102:
73-86,
2000.
29.
Sunderkötter, C,
Steinbrink K,
Goebeler M,
Bhardwaj R,
and
Sorg C.
Macrophages and angiogenesis.
J Leukoc Biol
55:
410-422,
1994[Abstract].
30.
Unger, EF,
Banai S,
Shou M,
Jaklitsch M,
Hodge E,
Correa R,
Jaye M,
and
Epstein SE.
A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs.
Cardiovasc Res
27:
785-791,
1993
31.
Van Royen, N,
Piek J,
Buschmann I,
Hoefer I,
Voskuil M,
and
Schaper W.
Stimulation of arteriogenesis: a new concept for the treatment of arterial occlusive disease.
Cardiovasc Res
49:
543-553,
2001
32.
Wolf, C,
Cai WJ,
Vosschulte R,
Koltai S,
Mousavipour D,
Scholz D,
Afsah-Hedjri A,
Schaper W,
and
Schaper J.
Vascular remodeling and altered protein expression during growth of coronary collateral arteries.
J Mol Cell Cardiol
30:
2291-2305,
1998[Web of Science][Medline].
33.
Yang, HT,
Yan Z,
Abraham JA,
and
Terjung RL.
VEGF(121)- and bFGF-induced increase in collateral blood flow requires normal nitric oxide production.
Am J Physiol Heart Circ Physiol
280:
H1097-H1104,
2001
This article has been cited by other articles:
![]() |
S H Schirmer, F C van Nooijen, J J Piek, and N van Royen Stimulation of collateral artery growth: travelling further down the road to clinical application Heart, February 1, 2009; 95(3): 191 - 197. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Niu, A. Azfer, O. Zhelyabovska, S. Fatma, and P. E. Kolattukudy Monocyte Chemotactic Protein (MCP)-1 Promotes Angiogenesis via a Novel Transcription Factor, MCP-1-induced Protein (MCPIP) J. Biol. Chem., May 23, 2008; 283(21): 14542 - 14551. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Duvall, D. Weiss, S. T. Robinson, F. M.F. Alameddine, R. E. Guldberg, and W. R. Taylor The Role of Osteopontin in Recovery from Hind Limb Ischemia Arterioscler Thromb Vasc Biol, February 1, 2008; 28(2): 290 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Y. Schubert, A. Benarroch, J. Ostvang, and E. R. Edelman Regulation of Endothelial Cell Proliferation by Primary Monocytes Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 97 - 104. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gray, I. M. Packham, F. Wurmser, N. C. Eastley, P. G. Hellewell, P. W. Ingham, D. C. Crossman, and T. J.A. Chico Ischemia Is Not Required for Arteriogenesis in Zebrafish Embryos Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2135 - 2141. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Seidler, M. C. Lenter, B. D. Guth, and H. Doods Short-Term Intra-Arterial Infusion of Monocyte Chemoattractant Protein-1 Results in Sustained Collateral Artery Growth Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 61 - 68. [Abstract] [PDF] |
||||
![]() |
O. Dewald, P. Zymek, K. Winkelmann, A. Koerting, G. Ren, T. Abou-Khamis, L. H. Michael, B. J. Rollins, M. L. Entman, and N. G. Frangogiannis CCL2/Monocyte Chemoattractant Protein-1 Regulates Inflammatory Responses Critical to Healing Myocardial Infarcts Circ. Res., April 29, 2005; 96(8): 881 - 889. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Voskuil, I. E Hoefer, N. van Royen, J. Hua, S. de Graaf, C. Bode, I. R Buschmann, and J. J Piek Abnormal monocyte recruitment and collateral artery formation in monocyte chemoattractant protein-1 deficient mice Vascular Medicine, November 1, 2004; 9(4): 287 - 292. [Abstract] [PDF] |
||||
![]() |
S. H. Schirmer, I. R. Buschmann, M. M. Jost, I. E. Hoefer, S. Grundmann, J.-P. Andert, S. Ulusans, C. Bode, J. J. Piek, and N. van Royen Differential effects of MCP-1 and leptin on collateral flow and arteriogenesis Cardiovasc Res, November 1, 2004; 64(2): 356 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Unthank, K. M. Sheridan, and M. C. Dalsing Collateral Growth in the Peripheral Circulation: A Review Vascular and Endovascular Surgery, July 1, 2004; 38(4): 291 - 313. [Abstract] [PDF] |
||||
![]() |
C. A.U. Heilmann, T. Attmann, A. Thiem, E. Haffner, F. Beyersdorf, and G. Lutter Gene therapy in cardiac surgery: intramyocardial injection of naked plasmid DNA for chronic myocardial ischemia Eur. J. Cardiothorac. Surg., November 1, 2003; 24(5): 785 - 793. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |